MedPath

NutriMind: A Combination of Healthy Diet and Psychotherapy to Treat Depression

Not Applicable
Recruiting
Conditions
Depression
Interventions
Behavioral: Mindfulness-based cognitive therapy (MBCT)
Other: Healthy Diet
Registration Number
NCT05848973
Lead Sponsor
University of Bergen
Brief Summary

University students in Low- and Middle-Income Countries (LMIC) continue to face growing rates of depression, a common mental health problem. Adding to this burden is the mental health treatment gap, necessitating the need to identify new treatment methods that can easily be implemented at a large scale.

This project will test if a healthy diet combined with mindfulness-based cognitive therapy can reduce depressive symptoms among university students in Uganda, a low resource country.

The burden of depression is high in sub-Saharan African countries, largely worsened by poverty, hunger and poor public health service, and lately the COVID-19 pandemic. These factors increase psychological distress among young people in sensitive periods of life, such as students who are about to choose their career and establish family. Successfully managing depression in LMIC is likely to depend on low-cost treatment that can easily be managed to large target populations, yet still be at the scientific forefront, proof-based, and culturally acceptable. This can possibly be obtained with an intervention combining healthy diet and cognitive behavioral therapy based on mindfulness principles.

While healthy diets and mindfulness cognitive therapy individually can partly lessen the burden of depression, these two therapeutic modalities have not been tested in combination among university students in sub-Saharan Africa, i.e. a synergistic effect that is still to be studied.

With the NutriMind Trial, its investigators focus on a neglected global mental health challenge, namely depression among university students in Uganda.

Detailed Description

Despite being a major global health issue for decades, Common Mental Health Problems (CMHPs), such as depression, remains neglected. University students worldwide are facing growing rates of CMHPs, with few or no mental health services available. The burden of CMHPs is highest in low- and middle-income countries (LMICs), largely worsened by poverty, hunger and poor public health governance. These factors increase stress, in particular among students who are about to choose their career, both in academia and later in the work force. Successfully managing CMHPs in LMICs is likely to depend on treatment methods that can easily be administered to the target population, yet still be at the scientific forefront, evidence-based, and culturally acceptable.

Wellness-based therapy includes behavioural changes like mindfulness-based cognitive therapies and nutritional interventions. While systematic reviews and randomized controlled trials show that such treatment modalities may lessen the burden of CMPHs, including depression, they have not been tested among university students in LMICs. The NutriMind investigators will therefore perform a randomized controlled trial to test if mindfulness-based cognitive therapy and/or a healthy diet (modified Mediterranean diet) will reduce depressive symptoms among university students in Uganda, a low-income country. In addition to evaluate the clinical outcomes, the investigators will analyse biomarkers for various metabolic pathways, as studies have related e.g. inflammation and oxidative stress to depression. Recent studies also indicate that the microbiome can play a role in depression through orchestrating metabolic signals to the brain. Notwithstanding these ambitious goals, our experienced and cross-disciplinary team puts us in an advantageous position to successfully accomplish this work.

The overall goal of the project is thus to test pragmatic lifestyle interventions in a population at high risk of depression in a low-resource setting and link the study outcomes to biological processes. If the investigators succeed, they can readily identify those who will improve from the intervention and provide an opportunity to respond to current gaps in mental health treatment, in particular in LMICs. In doing so, this novel project will address the World Health Organization's appeal for immediate and sustained action to reduce mental health illnesses, and the Lancet Commission's call for a substantial global shift toward healthy dietary patterns, as well as United Nations Sustainable Development Goals, in particular nos. 3 (good health and well-being) and 4 (quality education).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mindfulness-based cognitive therapy (MBCT)Mindfulness-based cognitive therapy (MBCT)The study participants randomized to this arm will be taught the purpose and application of MBCT, namely to modify cognitive and effective processes in the management of depressive symptoms as well as relapse prevention among those with residual depressive symptoms. It is a structured 8-weeks' intervention program delivered in groups, with an all-day practice session around week six and regular reunion sessions thereafter.
Healthy dietHealthy DietThe study participants randomized to this arm will be given advice about consuming a healthy diet, i.e. a diet rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; and moderate in red meat and dairy products. The participants will receive 8 weekly, one hour group sessions delivered by trained nutritionists.
Healthy diet and MBCT combinedMindfulness-based cognitive therapy (MBCT)The study participants randomized to this arm will receive both the healthy diet intervention and the MBCT intervention
Healthy diet and MBCT combinedHealthy DietThe study participants randomized to this arm will receive both the healthy diet intervention and the MBCT intervention
Primary Outcome Measures
NameTimeMethod
Change from baseline to 24 months in depressive symptoms using the Center for Epidemiological Studies - Depression (CES-D) score among the study participants randomized to each of the three intervention arms compared with the controls.24 months

Depressive symptoms will be assessed using the CES-D score from before to after the intervention. CES-D scores range from 0 to 60, with higher scores indicating greater depressive symptoms. The CES-D provides cut-off scores (16 or greater) to aid in identifying individuals at risk for clinical depression, with good sensitivity and specificity and high internal consistency.

Secondary Outcome Measures
NameTimeMethod
Change from baseline to 24 months in blood CRP levels among the study participants randomized to each of the three intervention arms compared with the controls.24 months

Blood CRP (mg/l) will be analyzed using standard biochemistry methods, levels above the reference range indicate increased risk of cardiovascular disease.

Change from baseline to 24 months in body composition among the study participants randomized to each of the three intervention arms compared with the controls.24 months

Body composition (i.e. percentage of fat, bone, water and lean body mass) will be assessed with bio-impedance.

The health economic costs of each of the three intervention arms compared with the control group.24 months

Health economic costs of the interventions on change in depressive symptoms will be evaluated using standard cost-effectiveness methods including sensitivity analysis. Investigators will convert the CES-D and BDI-II scores into a generic health measure (e.g. disability/quality adjusted life years) for this purpose.

Change from baseline to 24 months in fecal microbiota composition levels among the study participants randomized to each of the three intervention arms compared with the controls.24 months

Microbiota (percentage distribution of various bacteria) will be analysed feces using 16S rRNA amplicon sequencing. Less diverse microbiota composition may indicate increased risk of depression and other non-communicable diseases.

Change from baseline to 24 months in depressive symptoms using the Beck Depression Inventory-II (BDI-II) score among the study participants randomized to each of the three intervention arms compared with the controls.24 months

BDI-II is a self-reported, validated tool for screening depressive symptoms on a 4-point scale with 21 questions, giving a range of 0-63. A score \> 10 strongly indicates depression.

Change from baseline to 24 months in body weight among the study participants randomized to each of the three intervention arms compared with the controls.24 months

Weight in kilograms will be measured using a scale (to the nearest 100 g)

Change from baseline to 24 months in blood cholesterol levels among the study participants randomized to each of the three intervention arms compared with the controls.24 months

Blood cholesterol (mmol/l) will be analyzed using standard biochemistry methods, levels above the reference range indicate increased risk of cardiovascular disease.

Change from baseline to 24 months in body height among the study participants randomized to each of the three intervention arms compared with the controls.24 months

Height in meters will be measured using a scale (to the nearest cm)

Trial Locations

Locations (1)

Makerere University

🇺🇬

Kampala, Central Uganda, Uganda

© Copyright 2025. All Rights Reserved by MedPath